IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

IN RE BENDAMUSTINE CONSOLIDATED CASES) C.A. No. 13-2046-GM	
) (CONSOLIDATED)	

DEFENDANTS' NOTICE OF APPEAL

Notice is hereby given that Defendants Hetero Labs Ltd. and Hetero USA Inc.; InnoPharma, Inc.; Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd.; Hospira, Inc.; and Sagent Pharmaceuticals, Inc. in the above captioned matter (collectively, "Defendants") hereby appeal to the United States Court of Appeals for the Federal Circuit from the portions of the June 10, 2016, Order (D.I. 473, ¶¶ 1-3, 5) and the June 10, 2016 Memorandum (D.I. 472) holding not invalid certain asserted claims (*i.e.*, all asserted claims other than Claims 19-21 of U.S. Patent No. 8,791,270), and from all underlying or other decisions, orders, rulings, and findings adverse to Defendants.

Out of an abundance of caution, Defendants file this Notice of Appeal within thirty days of the Court's June 10, 2016 Order and Memorandum (D.I. 472, 473). Defendants do not believe that the Court's June 10, 2016 Order and Memorandum are final or appealable absent entry of Final Judgment, which has not occurred. However, Defendants file this Notice of Appeal now as a precautionary measure. (*See* Fed. R. App. P. 4(a)(2).) Defendants understand that the Court intends to enter Final Judgment at a later date, following the filing of the parties' proposed judgment(s). (D.I. 478.) Defendants may file a Supplemental Notice of Appeal as needed within thirty days of the entry of Final Judgment to further appeal from the portions of

the Final Judgment that hold asserted claims not invalid.

In accordance with 28 U.S.C. §§ 1913 and 1917, Rule 52 of the Federal Circuit Rules of Practice, and Federal Rule of Appellate Procedure 3(e), Defendants are submitting, contemporaneously with the filing of this Notice of Appeal, payment of \$505.00, representing the \$500.00 docketing fee and the \$5.00 filing fee.

/s/ Eve H. Ormerod

Neal C. Belgam (No. 2721) Eve H. Ormerod (No. 5369) SMITH, KATZENSTEIN & JENKINS LLP 1000 West Street, Suite 1501 P.O. Box 410 Wilmington, DE 19899 (302) 654-8400 nbelgam@skjlaw.com eormerod@skjlaw.com

OF COUNSEL:

Michael R. Dzwonczyk Azy S. Kokabi SUGHRUE MION, PLLC 2100 Pennsylvania Ave., N. W. Washington, DC 20037 mdzwonczyk@sughrue.com akokabi@sughrue.com

Counsel for Accord Healthcare Inc. and Intas Pharmaceuticals Ltd.

/s/ Samantha G. Wilson

Melanie K. Sharp (No. 2501)
Samantha G. Wilson (No. 5816)
YOUNG CONAWAY STARGATT & TAYLOR, LLP
Rodney Square
1000 North King Street
Wilmington, DE 19801
(302) 571-6881
msharp@ycst.com

Bradford P. Lyerla Sara Tonnies Horton Yusuf Esat JENNER & BLOCK LLP 353 N. Clark St. Chicago, IL 60654 -3456 (312) 222-9350

Counsel for Hospira, Inc.

/s/ Stamatios Stamoulis

Stamatios Stamoulis (No. 4606)
Richard C. Weinblatt (No. 5080)
STAMOULIS & WEINBLATT LLC
Two Fox Point Centre
6 Denny Road, Suite 307
Wilmington, DE 19809
(302) 999-1540
stamoulis@swdelaw.com
weinblatt@swdelaw.com

/s/ Shanti M. Katona

R. Montgomery Donaldson (No. 4367)
Shanti M. Katona (No. 5352)
POLSINELLI PC
222 Delaware Avenue, Suite 1101
Wilmington, Delaware 19801
Phone: (302) 252-0920
Fax: (302) 252-0921
rmdonaldson@polsinelli.com
skatona@polsinelli.com

OF COUNSEL:

Shashank Upadhye

Joseph E. Cwik

Jonathan J. Krit

AMIN TALATI & UPADHYE, LLC

100 S. WACKER DR.

SUITE 2000

CHICAGO, IL 60606

Phone: (312) 466-1033 Fax: (312) 884-7352

shashank@amintalati.com

joe@amintalati.com

Counsel for InnoPharma, Inc.

/s/ John M. Seaman

John M. Seaman (No. 3868) ABRAMS & BAYLISS LLP 20 Montchanin Road, Suite 200 Wilmington, DE 19807 (302) 778-1000 seaman@abramsbayliss.com

OF COUNSEL:

Neal Seth

Lawrence Sung

Karin Hessler

WILEY REIN LLP

1776 K St NW

Washington DC 20006

nseth@wileyrein.com

Counsel for Hetero Labs Ltd. and Hetero USA,

Inc.

Dated: July 11, 2016

OF COUNSEL:

Ronald M. Daignault

POLSINELLI PC

900 Third Avenue

21st Floor

New York, NY 10022

Phone: (212) 684-0199

Fax: (212) 684-0197

rdaignault@polsinelli.com

Counsel for Defendants Sagent Pharmaceuticals,

Inc.